8-K: Ampio Pharmaceuticals to Voluntarily Delist from NYSE American and Deregister with SEC

Ampio Pharmaceuticals has announced its decision to voluntarily delist from the NYSE American and deregister its common stock with the SEC, citing high costs and non-compliance with listing requirements.

Summary

• Ampio Pharmaceuticals has decided to voluntarily delist its common stock from the NYSE American.
• The company will also deregister its common stock with the Securities and Exchange Commission (SEC).
• This decision was made due to the high costs associated with maintaining the listing and the company's likely non-compliance with continued listing requirements.
• The company intends to file a Form 25 with the SEC on or about April 4, 2024, to initiate the delisting process.
• Trading of Ampio's common stock on the NYSE American is expected to cease on or about April 14, 2024.
• Following the delisting, the company plans to file a Form 15 with the SEC on or about April 15, 2024, to suspend its reporting obligations.
• The deregistration of the company's common stock is expected to become effective 90 days after the Form 15 filing.
• The company's decision is aimed at preserving cash to fund an orderly wind down of operations and maximize its cash position.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting, deregistration, and planned wind-down of operations. This indicates a significant downturn for the company and its investors.

Positives

• The company is taking steps to preserve cash by reducing operating expenses related to reporting requirements.
• The company is aiming to maximize its cash position, which could be beneficial for stakeholders during the wind-down process.

Negatives

• The company's stock will no longer be traded on the NYSE American.
• The company will cease its reporting obligations with the SEC, reducing transparency.
• The delisting is a result of likely non-compliance with continued listing requirements.
• The company is planning an orderly wind down of operations, indicating a significant change in its business strategy.

Risks

• The company may face challenges in retaining key personnel during the wind-down process.
• There is no assurance that any alternative will result in any distribution to or cash return to stockholders.
• The delisting is expected to negatively impact the price of the company's stock.
• Pending legal proceedings may adversely affect the company's cash position.
• The settlement of certain legal actions is subject to conditions and risks.

Future Outlook

The company plans to wind down operations and maximize its cash position, with the delisting and deregistration being key steps in this process. The company is focused on preserving cash and managing its remaining obligations.

Management Comments

• The Board has determined that it is in the Company's best interests that the Company take steps designed to ensure sufficient cash to adequately fund an orderly wind down of the Company's operations and to maximize the Company's cash position.

Industry Context

This announcement reflects a challenging situation for a small pharmaceutical company facing financial pressures and regulatory burdens. Delisting and deregistration are not uncommon for companies struggling to meet listing requirements and manage costs, especially after a major program failure.

Comparison to Industry Standards

• Delisting from major exchanges is a relatively common occurrence for companies that fail to meet listing requirements or face financial difficulties, such as the recent delisting of several small biotech companies from the NASDAQ.
• The decision to deregister with the SEC is a more drastic step, often taken by companies that are winding down operations or going private, similar to companies that have been acquired or have undergone significant restructuring.
• The focus on cash preservation and orderly wind-down is a standard approach for companies in similar situations, with examples including companies that have failed clinical trials or have been unable to secure further funding.

Legal Proceedings

• The company mentions pending legal proceedings that may adversely affect its cash position.

Stakeholder Impact

• Shareholders will experience a negative impact due to the delisting and potential loss of investment.
• Employees may be affected by the wind-down of operations.
• Creditors may face uncertainty regarding the company's ability to meet its obligations.

Next Steps

• File Form 25 with the SEC on or about April 4, 2024.
• Delist from the NYSE American on or about April 14, 2024.
• File Form 15 with the SEC on or about April 15, 2024.
• Complete the deregistration process 90 days after filing Form 15.

Key Dates

Keywords

delisting, deregistration, NYSE American, SEC, reporting obligations, wind down, Form 25, Form 15, operating expense, cash preservation